Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalcetrapib in Acute Coronary Syndrome with ADCY9 AA Genotype
NCT05918861Phase 3Recruiting
- Sponsor
- DalCor Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Dalcetrapib with Placebo (2 arms). Primary endpoint: Time to first occurrence of any fatal or non-fatal myocardial infarction (MI) at 30 months. Started Oct 2023; status: recruiting.
02
Drugs
dalcetrapib
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05918861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918861.